Pharmacokinetic Evaluation of Cefazolin in the Cerebrospinal Fluid of Critically Ill Patients
| العنوان: | Pharmacokinetic Evaluation of Cefazolin in the Cerebrospinal Fluid of Critically Ill Patients |
|---|---|
| المؤلفون: | Alison R Novak, Martin Krsak, Tyree H Kiser, Robert T Neumann, Luis Cava Prado, Kyle C Molina, Scott W Mueller |
| المصدر: | Open Forum Infectious Diseases |
| بيانات النشر: | Oxford University Press, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | cerebrospinal fluid shunts, critical care, Infectious Diseases, AcademicSubjects/MED00290, Oncology, polycyclic compounds, Major Article, distribution, cefazolin, critical illness, pharmacokinetics, cerebrospinal fluid |
| الوصف: | Background The relative distribution of cefazolin into the cerebrospinal fluid (CSF) remains debated. Determining the distribution of cefazolin into the CSF in noninfected adults may allow for further treatment applications of cefazolin. This prospective pharmacokinetic study aimed to determine the pharmacokinetic parameters of cefazolin in serum and CSF from external ventricular drains (EVDs) in neurologically injured adults. Methods Blood and CSF were collected, using a biologic waste protocol, for cefazolin quantification and trapezoidal rule–based pharmacokinetic analysis in a total of 15 critically ill adults receiving 2000 mg intravenously every 8 hours or the renal dose equivalent for EVD prophylaxis. Results A median (range) of 3 (2–4) blood and 3 (2–5) CSF samples were collected for each patient. The most common admitting diagnosis was subarachnoid hemorrhage (66.7%). The median calculated cefazolin CSF Cmax and Cmin values (interquartile range [IQR]) were 2.97 (1.76–8.56) mg/L and 1.59 (0.77–2.17) mg/L, respectively. The median (IQR) CSF to serum area under the curve ratio was 6.7% (3.7%–10.6%), with time-matched estimates providing a similar estimate (8.4%). Of those receiving cefazolin every 8 hours, the median and minimum directly measured CSF cefazolin concentration ≥4 hours following administration were 1.87 and 0.78 mg/L, respectively. Conclusions Cefazolin dosed for EVD prophylaxis achieved CSF concentrations suggesting viability as a therapeutic option for patients with meningitis or ventriculitis due to susceptible bacteria such as methicillin-susceptible Staphylococcus aureus. Further clinical trials are required to confirm a role in therapy for cefazolin. Population-based pharmacokinetic–pharmacodynamic modeling may suggest an optimal cefazolin regimen for the treatment of central nervous system infections. D/C/F/TAF is the reference for combination therapy based on protease inhibitors but has not been compared with regimens containing integrase inhibitors as initial ART. We could not demonstrate D/C/F/TAF noninferiority relative to DTG/ABC/3TC, although both regimens were similarly well tolerated. |
| اللغة: | English |
| تدمد: | 2328-8957 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79b8f11b1f52c10779c63e5c287072cc http://europepmc.org/articles/PMC8802796 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....79b8f11b1f52c10779c63e5c287072cc |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 23288957 |
|---|